NPI: 1639699440 · BALTIMORE, MD 21218 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 06/22/2017
Authorized official WINSTEL, JOHN controls 20+ related entities in our dataset. Read more
| Authorized Official | WINSTEL, JOHN (CHIEF ACCOUNTING OFFICER) |
| NPI Enumeration Date | 06/22/2017 |
Other providers sharing the same authorized official: WINSTEL, JOHN
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 15,601 | $29K |
| 2019 | 13,259 | $67K |
| 2020 | 12,197 | $165K |
| 2021 | 14,781 | $189K |
| 2022 | 9,756 | $153K |
| 2023 | 7,225 | $176K |
| 2024 | 4,534 | $164K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 90999 | Unlisted dialysis procedure, inpatient or outpatient | 13,030 | 1,835 | $667K |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 32,166 | 1,774 | $119K |
| J0887 | Injection, epoetin beta, 1 microgram, (for esrd on dialysis) | 370 | 209 | $82K |
| J1270 | Injection, doxercalciferol, 1 mcg | 13,333 | 1,342 | $39K |
| J1756 | Injection, iron sucrose, 1 mg | 5,641 | 1,469 | $20K |
| 83970 | 1,666 | 1,505 | $15K | |
| A4657 | Syringe, with or without needle, each | 2,691 | 2,076 | $855.06 |
| 85041 | 1,998 | 1,748 | $0.00 | |
| 85048 | 1,955 | 1,709 | $0.00 | |
| 83540 | 1,074 | 923 | $0.00 | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 1,347 | 961 | $0.00 |
| 83550 | 1,001 | 861 | $0.00 | |
| 82728 | 967 | 840 | $0.00 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 58 | 56 | $0.00 |
| J0604 | Cinacalcet, oral, 1 mg, (for esrd on dialysis) | 56 | 37 | $0.00 |